Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter infection.

BACKGROUND Campylobacter species is a leading cause of bacterial gastroenteritis worldwide. Quinolone resistance has emerged as an increasing problem among persons with Campylobacter infection over the past decade, but the clinical consequences are unclear. METHODS A case-comparison study of patients infected with ciprofloxacin-resistant or ciprofloxacin-susceptible Campylobacter species was conducted in Wales during the period 2003-2004. Campylobacter isolates were classified as resistant or susceptible to ciprofloxacin on the basis of standardized disk diffusion methods. Participants were interviewed by telephone at the time of illness, 3 months later, and 6 months later to compare disease severity, duration of illness, and medium-term clinical outcomes. RESULTS There was no difference between 145 persons with ciprofloxacin-resistant infection and 411 with ciprofloxacin-susceptible infection with regard to the severity or duration of acute illness. Mean duration of diarrhea was similar in patients with ciprofloxacin-resistant versus ciprofloxacin-susceptible infection (8.2 vs. 8.6 days; P = .57) and did not alter significantly after adjustment for potential covariates, including age, underlying disease, foreign travel, use of antidiarrheal medication, and use of antimicrobials in a multiple linear regression model. There was no difference between case patients and comparison patients in the frequency of reported symptoms or in general practitioner consultation rates at either the 3-month or the 6-month follow-up interview. CONCLUSIONS In this study, there was no evidence of more-severe or prolonged illness in participants with quinolone-resistant Campylobacter infection, nor was there evidence of any adverse medium-term consequences. This suggests that the clinical significance of quinolone resistance in Campylobacter infection may have been overestimated.

[1]  P. Silley Campylobacter and fluoroquinolones: a bias data set? , 2003, Environmental microbiology.

[2]  T. Wassenaar,et al.  Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. , 2007, International journal of antimicrobial agents.

[3]  N. Marano,et al.  Prolonged diarrhea due to ciprofloxacin-resistant campylobacter infection. , 2004, The Journal of infectious diseases.

[4]  K. Travers,et al.  Morbidity of infections caused by antimicrobial-resistant bacteria. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Tompkins,et al.  Ciprofloxacin resistance in Campylobacter jejuni: case-case analysis as a tool for elucidating risks at home and abroad. , 2002, The Journal of antimicrobial chemotherapy.

[6]  K. Mølbak,et al.  Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. , 2005, The Journal of infectious diseases.

[7]  L B Reller,et al.  Practice guidelines for the management of infectious diarrhea. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Silley Campylobacter and fluoroquinolones: a bias data set? Environ Microbiol , 2003 .

[9]  Rian,et al.  QUINOLONE-RESISTANT CAMPYLOBACTER JEJUNI INFECTIONS IN MINNESOTA , 1992 – 1998 , 2022 .

[10]  F. Aarestrup,et al.  Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. , 2001, Emerging infectious diseases.

[11]  J. Giesecke,et al.  A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  F. Aarestrup,et al.  Quinolone-resistant Campylobacter Infections: Risk Factors and Clinical Consequences , 2004, Emerging infectious diseases.

[13]  A. King Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. , 2001, Journal of Antimicrobial Chemotherapy.

[14]  J. Giesecke,et al.  Case-case comparisons to study causation of common infectious diseases. , 1999, International journal of epidemiology.

[15]  F. Aarestrup,et al.  Quinolone-resistant Campylobacter Infections in Denmark: Risk Factors and Clinical Consequences 1 , 2004 .

[16]  Louis Anthony Cox,et al.  Ciprofloxacin resistance does not affect duration of domestically acquired campylobacteriosis. , 2005, The Journal of infectious diseases.

[17]  M. Pasternack Impact and management of Campylobacter in human medicine--US perspective. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  A. Lastovica,et al.  The epidemiology of antibiotic resistance in Campylobacter. , 2006, Microbes and infection.

[19]  G. Ruiz-Palacios The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Kirk,et al.  Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Kist Impact and management of Campylobacter in human medicine--European perspective. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  K. Mølbak Human health consequences of antimicrobial drug-resistant Salmonella and other foodborne pathogens. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Wallace,et al.  The role of antibiotics in the treatment of infectious diarrhea. , 2001, Gastroenterology clinics of North America.